Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.44 |
| ▸ | TSHR | P16473 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22808138 | 0.84 | ATM (0.42) | ATMCYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL27756335 | 0.79 | CYP3A4 (0.46) | ATMCYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL28580670 | 0.79 | CYP3A4 (0.46) | ATMCYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4658795 | 0.79 | CYP3A4 (0.46) | ATMCYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL27756338 | 0.79 | CYP3A4 (0.46) | ATMCYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL13691987 | 0.79 | CYP3A4 (0.46) | ATMCYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL12540247 | 0.79 | CYP3A4 (0.46) | ATMCYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL27756333 | 0.79 | CYP3A4 (0.46) | ATMCYP3A4TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3361383 | 0.75 | CTSL (0.52) | ATMCYP3A4TSHRALDH1A1MEN1 | |
| SCHEMBL20830135 | 0.74 | CA1 (0.36) | CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870671-B2 | Method of preparation of alpha galactosyl ceramides compounds | ABIVAX (FR) | 2020-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870671-B2 | Method of preparation of alpha galactosyl ceramides compounds | UGCG, GBA1, MAN2B1 | ATM 4668/4885CYP3A4 2855/4885TSHR 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.